Home Science Oxford University Temporarily Halts Vaccine Trials Amid Suspected Side Effect In A...

Oxford University Temporarily Halts Vaccine Trials Amid Suspected Side Effect In A Participant From UK

Oxford-AstraZeneca COVID-19 vaccine has been put on a halt due to some "unexplained illness" detected in one of the recipients of the inoculation. 

Clinical trials of Oxford-AstraZeneca COVID-19 vaccine has been put on a halt due to some “unexplained illness” detected in one of the recipients of the inoculation. 

Stat News got a statement from AstraZeneca that confirmed the pause of the trials. In the report, a spokesperson from AstraZeneca stated that the break was triggered during a standard review process to permit evaluation of safety data. The spokesperson also noted that the company is conducting a thorough review of the single event to prevent prolonged delays.  

WireX August Download

BBC’s medical correspondent, Fergus Walsh tweeted: “Oxford University/AstraZeneca coronavirus vaccine trial put on hold while suspected adverse reaction independently investigated. My understanding is this is standard procedure when anyone who is on a vaccine trial is admitted to hospital, and their cause of illness is unknown.”

This is the second such halt in the vaccine trial. Experts believe that the tests are likely to resume in a few days.

Talking about the abruption, an Oxford University spokesperson stated:

In large trials, illnesses will happen by chance but must be independently reviewed to check this carefully.

Oxford-AstraZeneca vaccine’s Phase 3 trials commenced in the U.S. in late August. Phase 2/3 trials were initiated earlier in U.K., Brazil, and South Africa. It is suspected that the adverse reaction occurred during Phase 2/3 trials in the U.K. 

Oxford’s vaccine is one of the top contenders in the vaccine race and has consistently shown successful results in the earlier stages of clinical trials. In fact, the Serum Institute of India (SII) was also conducting the Phase 3 trials of this vaccine candidate, also called Covishield in India. On Monday, CEO of SII, Adar Poonawalla tweeted: “Proud and excited for the next few months and looking forward to the vaccine.”

In India, apart from Covishield, trials are underway for Bharat Biotech’s ‘Covaxin’, and Zydus Cadila’s ‘ZCOV-D’. 


WireX August Download

Muskan Bagrecha
Muskan is an undergraduate student pursuing a Bachelor's in Technology. With a zealous spirit for writing, she finds herself open to the vast realm of learning. She is an avid programmer with a keen interest in technology and science.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Global 5G chipset market forecasted to reach USD 22,929 Million by 2026

The growing demand for mobile data services is expected to increase the 5G chipset market size growth The global 5G Chipset market size is expected...

Government aims to setup one EV charging station for every 69,000 petrol pumps

To speed up the process, the government has also reduced 5% GST on electric vehicles In an effort to boost electric vehicle production in India,...

Samsung’s next wireless earbuds may “ditch” the Bean-shaped design

Samsung gained a lot of attention for its launch of beans-shaped Galaxy Buds Live Earbuds this year. Although at first, it seemed like the...

Why was Infinix Zero 8i launch delayed to Dec 3rd

Earlier in November, reports online began hinting that Infinix is gearing up to launch the new ‘Zero’ Series in India. The Infinix Zero 8...

Recent Comments